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Abstract: This paper reports on the in vitro antimicrobial activity of ampicillin-ceftriaxone and ampicillin-ertapenem 
combinations against five strains of E. faecalis with high-level aminoglycoside resistance recovered from blood of septi-
cemic patients. Double disk diffusion test and time killing curves were used. A bacteriostatic synergistic effect between 
ampicillin and ceftriaxone was detected using the disk diffusion assay for three of the five enterococcal strains studied. 
With the same three isolates enhanced bactericidal activity was also observed using time killing experiments. Overall, for 
these three strains, after 24 hr of contact, a decrease  2 log10 from the initial bacterial inoculum was registered with most 
ampicillin-ceftriaxone combinations, reaching with some of them a colony reduction  3 log10. This bactericidal interac-
tion was negatively influenced increasing the bacterial inoculum. In all five isolates neither a bacteriostatic nor a bacteri-
cidal cooperation was observed for ampicillin combined with 2 mg/l of ertapenem. 
This investigation broadened the evidence of antimicrobial synergism in vitro between ampicillin and ceftriaxone in selec-
ted strains of Enterococcus faecalis with high-level aminoglycoside resistance. 
BACKGROUND 
Enterococci have been reported as major cause of ac-
quired nosocomial infections including urinary tract infec-
tions, intra-abdominal and pelvic infections, bacteremia, 
endocarditis and meningitis. Enterococcus faecalis is re-
sponsible for about 80-90% of all enterococcal infections 
[1]. Severe enterococcal infections require a bactericidal 
therapy, which is usually a combination of a cell wall active 
agent such as ampicillin, penicillin or a glycopeptide plus 
gentamicin or streptomycin. However, the increasing resis-
tance to high levels of aminoglycosides (HLAR) and to other 
antimicrobials leads to the loss of effective synergisms and 
thus bactericidal activity [1, 2]. 
Enterococci are considered to be resistant to cepha-
losporins. Nonetheless, a synergistic effect between penicil-
lin and cephalosporins has been reported in several in vitro 
studies. Mainardi observed an in vitro synergism between 
amoxicillin and cefotaxime in 48 out of 50 E. faecalis strains 
due to the saturation of PBPs 2 and 3 by cefotaxime in addi-
tion to the partial saturation of PBPs 4 and 5 with amoxicil-
lin [3]. In another experiment, a synergistic effect between 
the two antimicrobials was not obtained in E. faecalis rabbit 
endocarditis because of the brief period of time in which 
amoxicillin and cefotaxime concentrations remained in the  
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range required to obtain synergism [4]. Gavaldà demon-
strated a synergistic effect between ampicillin and ceftriax-
one in vitro as well as in an experimental model of E. fae-
calis endocarditis [5-7]. The same author reported at three 
months an overall cure rate of 67.4% among 43 patients with 
E. faecalis endocarditis, 21 HLAR and 22 non-HLAR [6]. 
Others reported controversial results [8, 10]. 
Enhanced bactericidal activity has been shown for am-
picillin combined with imipenem in E. faecium experimental 
endocarditis [11]. Ertapenem is another carbapenem antibi-
otic with a broad spectrum of antibacterial activity against 
anaerobic and aerobic Gram negative bacteria, excluding the 
non-fermenters, and anaerobic and aerobic Gram positives, 
excluding methicillin resistant Staphylococcus aureus and 
enterococci [12-14]. In contrast to imipenem, it is less active 
against  Pseudomonas  spp.,  Acinetobacter spp. and Gram-
positive pathogens due to the poor affinity of the PBPs of 
these micoorganisms [12-14]. 
The purpose of this work was to further analyse the in vi-
tro interaction between amipicillin and ceftriaxone and to 
evaluate that of ampicillin-ertapenem combination against 
five high-level aminoglycoside resistant E. faecalis strains 
isolated from patients with bacteremia. 
METHODS  
Bacterial strains. Five strains of E. faecalis isolated 
from bacteremic patients were studied. Bacterial identifica-
tion was verified by standardized procedures (API 20 Strep, 
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Before each experiment aliquots were thawed and sub-
cultured in 5% sheep Columbia agar plates. 
Antibiotic susceptibility studies. Beta-lactamase pro-
duction was assessed with the nitrocephin disk test (Becton 
Dickinson, Sparks, Maryland, USA). Antibiotic susceptibil-
ity was determined by agar diffusion [15]. Etest (AB-
BIODISK, Solna, Sweden), and with the Phoenix microdilu-
tion (Becton Dickinson) methods. For ampicillin, ceftriaxone 
and ertapenem MICs and MBCs were determined also using 
the standard macrodilution method in Müller-Hinton broth 
(MHB) with a bacterial inoculum of 2-5x10
5 CFU/ml [16-
17]. Stock solutions of ampicillin, ceftriaxone or ertapenem 
were prepared and stored at -20°C until the day of use. To 
determine bactericidal activity of antibiotics 0.1 ml of the 
bacterial suspensions from each dilution tube were sub-
cultured in Müller-Hinton agar (MHA) plates [18].  Plates 
were incubated at 37°C for 24 and 48 hours and colonies 
were counted at the same times. An effect was considered 
bactericidal when killing of 10
3 CFU/ml from the initial 
inoculum was recorded [18]. E. faecalis ATCC 29212 was 
used as control strain. 
Synergy studies. A qualitative estimation (bacteriostatic 
activity) of the synergy between ampicillin and ceftriaxone 
or ampicillin and ertapenem was first evaluated utilizing the 
double disk method on MHA plates [19]. The disk antibiotic 
concentrations were as follows: ampicillin, 10 μg 
(BioMerieux); ceftriaxone, 30 μg (BioMerieux); ertapenem, 
10 μg (Becton Dickinson). 
Time killing studies were performed in MHB supple-
mented with several concentrations of ampicillin, ceftriax-
one, and ertapenem [5, 19]. The final antibiotic concentra-
tions were the following: ampicillin 0.5, 1, 2 and 4 mg/l (be-
tween MIC and sub-inhibitory concentrations); ceftriaxone 
10, 20, 40 and 80 mg/l, between peak and trough values dur-
ing patient treatment; ertapenem 2 mg/l, trough value. The 
bactericidal activity was evaluated for ampicillin alone or in 
combination with ceftriaxone or ertapenem. Test tubes were 
inoculated with a suspension of enterococcal strains at a final 
concentration of 2-5x10
5 CFU/ml or 2-5x10
7 CFU/ml and 
incubated at 37°C. A tube without antibiotics was used as 
positive growth control. The number of CFU/ml was ob-
tained at time 0, after 4 and 24 hours of incubation plating on 
MHA a number of different dilutions from each tube. Data 
are the mean of CFU recorded for each plate. To reduce the 
carry over effect the inoculum was spread over the entire 
plate surface after the broth had dried [19].  
To define antimicrobial interactions the criteria previ-
ously applied [5, 20] have been utilized. Antimicrobial inter-
actions were defined as additive when a  2 log10 CFU/ml 
decrease between the combination and its most active agent 
alone was registered after 24 hr. If the reduction reached  3 
log10 the combination was considered to have a synergistic 
effect [5, 20]. 
RESULTS 
The five E. faecalis strains in the study were isolated 
from blood. Three were from patients with central line re-
lated sepsis, one from a patient with a liver abscess and an-
other from a patient with prosthetic valve endocarditis (Table 
1). All the five strains were beta-lactamase negative. MIC 
values indicate that they were susceptible to ampicillin, line-
zolid, glycopeptides and resistant to ceftriaxone and ertap-
enem (Table 1). All the isolates were highly resistant to ami-
noglycosides. Isolate 2927 had gentamicin MIC >500 mg/l, 
and streptomycin MIC 64 mg/l, while strain 2980 had gen-
tamicin and streptomycin MIC respectively 8 mg/l and 
>1000 mg/l. The other three strains were both gentamicin 
and streptomycin resistant (Table 1).  
After 24 hours of incubation MBCs of ampicillin varied 
from 4 to above 32 mg/l (Table 2), producing a bactericidal 
effect (99.9% killing of the initial bacterial inoculum) in four 
out of five strains. Only one strain (2980) appeared to be 
tolerant to ampicillin. Intermediate concentrations of am-
picillin (2 and 4 mg/l) produced more efficacious bacterial 
killing for strains 2927 and 2980 (Table 2). MICs of cef-
triaxone and ertapenem were consistent with the resistance 
break points, therefore sub-cultures for MBC evaluations 
were not obtained. 
A bacteriostatic synergistic effect between ampicillin and 
ceftriaxone, recorded with two + in Table 2, was observed 
with the disk diffusion assay for three of the five enterococ-
cal strains evaluated (Table 3). In broth, ampicillin MICs did 
not change or decreased of only one tube dilution when ei-
ther ceftriaxone or ertapenem at concentrations of 10 mg/l 
and 2 mg/l, respectively, were added (Table 3). 
The time killing curves of ampicillin alone or in combi-
nation with 10 mg/l ceftriaxone showed after four hours of 
Table 1. Antimicrobial Susceptibility of Five Enterococcus faecalis Clinical Isolates 
.  MIC 
(mg/l) 
Strain  Diagnosis  A L V T C E G S 
2557 Liver  abscess  4  2  2  1 >256 32 >500  >1000 
2648 CVC
a related sepsis   4  2  4  1 >256 64 >500  >1000 
2927 CVC  related  sepsis  1  2  2 1 >256 32 >500 64 
2929 Endocarditis 1  2  2  1 >256 16 >500  >1000 
2980 CVC  related  sepsis  2  2  4 1 >256 16  8 >1000 
A, ampicillin; C, ceftriaxone; E, ertapenem; G, gentamicin; L, linezolid; S, streptomycin; T, teicoplanin; V, vancomycin. 
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contact that 4 mg/l ampicillin produced a bacteriostatic effect 
with colony counts ranging from minus 0.3 to minus 2.9 
log10 in all the strains (Table 4). At the same intervals, a bac-
teriostatic effect was also observed with 2 mg/l ampicillin 
for strains 2929 and 2980 and 1 mg/l against strain 2980. 
Ceftriaxone alone (10 mg/l) did not produce bacteriostatic 
effect. The addition of ceftriaxone (10 mg/l) to ampicillin did 
not modify the antibacterial activity of ampicillin for strains 
2557 and 2648 either after 4 or 24 hr. On the contrary, a 
positive bactericidal interaction resulted for strains 2927, 
2929 and 2980. Indeed, the combination 4 mg/l ampicillin-
ceftriaxone produced a bactericidal effect for strains 2927 
and 2980, 2 mg/l ampicillin-ceftriaxone for strains 2929 and 
2980, 1 mg/l ampicillin-ceftriaxone for strain 2929. Overall, 
after 24 hr a synergism was recorded for the combinations 4 
mg/l, 1 mg/l, 2 mg/l ampicillin-ceftriaxone against strains 
2927, 2929 and 2980 respectively, while an additive effect 
was seen with the combinations 0.5 mg/l ampicillin-
ceftriaxone against isolates 2927, 2929, and 2 mg/l ampicil-
lin-ceftriaxone against strain 2927. Using an higher bacterial 
inoculum (10
7 CFU/ml) the synergism ampicillin-ceftriaxone 
was still detected only with 2 mg/l ampicillin for the isolate 
2980 (data not shown). The synergism between ampicillin-
ceftriaxone was not affected when 2 mg/l of ampicillin was 
combined with increasing ceftriaxone concentrations (Table 
4).  
In all the experiments the bactericidal activity of ampicil-
lin was never decreased by ceftriaxone. 
When ampicillin was combined with 2 mg/l of ertapenem 
non consistent positive or negative interactions were regis-
tered against the strains tested (Table 4). 
DISCUSSION 
High levels of gentamicin and streptomycin resistances 
preclude bactericidal synergism with penicillin, ampicillin or 
glycopeptides for serious enterococcal infections. In these 
clinical situations other antimicrobial associations [2-11] 
have been evaluated but, given that their clinical data have 
not been fully conclusive, further investigations are needed. 
At the same time, other new additional associations need to 
be explored. Enterococci are considered intrinsically resis-
tant to cephalosporins [1, 2, 15]. Ertapenem is also reported 
to be inactive against enterococci [12-14]. Several authors 
have observed enhanced in vitro bactericidal activity of am-
picillin combined with cephalosporins [3-8]. Other research-
ers have observed enhanced activity of the combination am-
picillin-imipenem against E. faecium in experimental endo-
carditis [11].  
In this study, the antimicrobial activity of ampicillin 
alone and in combination with ceftriaxone or ertapenem in 
five strains of high-level gentamicin and streptomycin resis-
Table 2. Activity of Different Ampicillin Concentrations Against Five Isolates Enterococcus faecalis Highly Resistant to Aminoglyco-
sides 
                                                          Ampicillin Concentrations (mg/l) 
Strain 
Ampicillin MIC 
(mg/l) 
Ampicillin 
MBC (mg/l) 
0.5  1 2 4 8  16  32 
2557 4  16  >2  >2  >2  -0.3  -2.3  -4.0 -4.0 
2648 4  8  >2  >2  >2  -1.5  -3.0 -3.2 -3.8 
2927 2  32  >2  >2  -4.0 -3.9 -2.9 -2.4 -3.4 
2929 1  4  >2  -1.9  -1.9  -3.8 -3.8 -3.8 -3.8 
2980 2  >32  >2  >2  -3.0 -3.2 -2.6 -2.6 -2.6 
Values are change in log 10 CFU/ml 
 
Table 3. Bacteriostatic Interactions Between Ampicillin Plus Ceftriaxone or Ertapenem Against Five Isolates of Enterococcus faecalis 
Highly Resistant to Aminoglycosides Using the Double Disk Diffusion and the in Broth MIC Methods 
        Disk Diffusion Synergism  MIC (mg/l) 
Strain A  C  E  A+C A+E  A+C 
a
  A+E 
b
 
2557 4  >256  32  -  -  2  2 
2648 4  >256  64  -  -  2  2 
2927 1  >256  32  ++  -  2  2 
2929 1  >256  16  ++  -  0.5  0.5 
2980 2  >256  16  ++  -  2  2 
A, ampicillin; C, ceftriaxone; E, ertapenem. 
a, MIC of ampicillin in Muller Hinton Broth with a fixed ceftriaxone concentration (10 mg/l). 
b, MIC of ampicillin in Muller Hinton Broth with a fixed ertapenem concentration (2 mg/l). 82    The Open Microbiology Journal, 2008, Volume 2  Pasticci et al. 
tant E. faecalis isolated from bacteremic patients was evalu-
ated by both double disk diffusion and time killing methods.  
With the broth macromethod MBC test, ampicillin alone 
produced a bactericidal effect (99.9% killing of the initial 
bacterial inoculum) in four out of five strains at concentra-
tions equal or above those used for time killing experiments. 
Only one strain appeared to be tolerant to ampicillin. It is 
widely known that most enterococci are less likely killed at 
elevated concentrations of beta-lactam antibiotics [5, 9, 19]. 
Thus, the bactericidal effect of ampicillin in these experi-
ments may have been due to the tested ampicillin concentra-
tions which were very close to the MICs. Consequently, we 
may have been unable to evaluate the ampicillin tolerance of 
these strains [19]. Nevertheless, the purpose of the study was 
not to evaluate the ampicillin tolerance but rather to evaluate 
if any in vitro synergistic activity existed between ampicillin 
and ceftriaxone or ampicillin and ertapenem for these iso-
lates.  
Coming to this point, in broth MIC of ampicillin did not 
changed when a 10 mg/l concentration of ceftriaxone was 
Table 4. Results of Time-Killing Experiments with Five Isolates Enterococcus faecalis Highly Resistant to Aminoglycosides: Change 
in log10 CFU/ml from Initial Inoculum (2-5X10
5 CFU/ml) 
Enterococcus faecalis Strains 
 2557
   2648 2927  2929  2980 
Antimicrobials 
(mg/l) 
4 h  24 h  4h  24h  4h  24h  4h  24h  4h  24h 
None    +1.2  +3.4  +1.2 +3.0 +2.5 +2.8 +0.6  +3.0  +2.5  +3.2 
                 
A(0.5)  +0.8  +2.5  +1.4 +2.3 +2.4 +2.6 +0.3  +1.8  +0.3  +3.0 
A(1)  +0.8  +2.2  +1.4 +2.3 +2.1 +2.6  0  +1.1  -0.4  +1.9 
A(2)  +0.6  +1.5  +0.5 +1.3 +0.7 +0.4 -0.9 -2.5 -0.7  +1.5 
A(4)  -0.3  -0.2  -0.9 -1.0 -2.0 -0.3 -1.9  -3.5  -1.8 -2.4 
                 
C(10)  +1.2  +3.7  +0.8 +2.9 +1.1 +3.0 +0.5  +2.2  -0.2  +2.6 
                 
A(0.5)+C(10)  +1.0  +2.3  +1.5 +2.1 +0.6 +0.4 -0.9 -0.7 -1.7  +2.6 
A(1)   +C(10)  +0.8  +1.9  +1.5  +1.7  -0.9  +1.4  -1.2  -3.4  -2.5 +2.4 
A(2)   +C(10)  +0.7  0  +0.1  +1.1  -2.9  -1.6  -1.6  -3.0  -2.9  -4.0 
A(4)   +C(10)  -0.5  -0.6  -0.6  -0,9  -2.7  -3.7  -2.2  -3.8  -2.9  -3.4 
                    
A(2)+C(20) -0.5  +1.4  +0.6  +2.0  -2.0  -2.1  -1.2  -3.6  -2.3  -3.0 
A(2)+C(40) -0.5  +1.2  +0.6  +1.5  -2.0  -2.3  -2.0  -3.7  -2.2  -3.1 
A(2)+C(80) -0.8  +2.0  +0.6  +2.2  -2.0  -3.0  -1.0  -4.0  -3.3  -3.5 
                    
E(2)  +0.9  +2.6  +1.8 +2.2 +2.1 +2.7 +0.2  +2.2  +1.8  +2.9 
                    
A(0.5)+E(2)  +0.6  +1.8  +1.7 +1.9 +1.9 +2.4 -0.5 +1.8  +2.1  +2.6 
A(1)   +E(2)  +0.3  +1.2  +1.4  +1.6  +1.4  +1.4  -0.9  -0.9  +1.8  +3.0 
A(2)   +E(2)  -0.2  +0.4  +0.9  +0.5  -0.6  +0.9  -1.2  -3.0  -1.8 +2.4 
A(4)   +E(2)  -0.8  +0.1  -0.7  -0.7  -2.0  -0.4  -1.2  -3.0  -2.2 -2.9 
A, ampicillin; C, ceftriaxone; E, ertapenem.  
Numbers in parenthesis are mg/l. 
Values are change in log10 CFU/ml from initial inoculum. 
In bold concentrations showing bactericidal activity (decrease  3 log10). In vitro Antimicrobial Activity of Ampicillin-Ceftriaxone  The Open Microbiology Journal, 2008, Volume 2    83 
added. On the contrary an increased antimicrobial activity of 
ampicillin and ceftriaxone was evidenced with the double 
disk test and the time killing curves in three out of five 
strains. With this last technique, non bactericidal concentra-
tions of ampicillin produced an effective bacterial killing 
when ceftriaxone was added and some of the ampicillin-
ceftriaxone combinations showed a real synergistic interac-
tion. Other researchers have shown that saturation of differ-
ent bacterial PBPs with ampicillin and ceftriaxone is respon-
sible for the enhanced bacterial killing of this antimicrobial 
combinations [5] and that the effect was persistent for all the 
isolates tested [5]. Further experiments with an increased 
number of HLAR E. faecalis isolates will help to confirm 
strain variability to the ampicillin-ceftriaxone combination. 
More over, better standardized definitions of antimicrobial 
interactions will help to reduce variability among different 
studies [21]. 
All together, the results obtained on ampicillin-
ceftriaxone interactions with this small investigation broad-
ened the evidence of bacteriostatic and bactericidal syner-
gism in vitro between ampicillin and ceftriaxone. This effect 
was evident only for three of the five strains evaluated and 
was not influenced by the ceftriaxone concentrations. Until 
further in vitro and clinical data are collected, this combina-
tion could be used only in selected clinical situations such as 
infections caused by highly antimicrobial resistant E. fae-
calis or the occurrence of treatment adverse events [10]. 
The data on ampicillin-ertapenem combination did not 
show in vitro synergism either with disk diffusion and time 
killing curves when an ertapenem concentration of 2 mg/l 
(concentration observed at trough during patient treatment) 
was added to ampicillin for all the five strains in the study. 
Given this, the bactericidal interactions with ertapenem con-
centrations higher than 2 mg/l was not investigated. Differ-
ences in ertapenem affinity for enterococcal PBPs may be a 
reason for the absence of antibacterial activity of this combi-
nation [22-25].  
In conclusion, the results of this in vitro study broadened 
the evidence of bacteriostatic and bactericidal synergism in 
vitro between ampicillin and ceftriaxone. The effect was 
evident only for three of the five strains evaluated and was 
not influenced by the ceftriaxone concentrations. Double 
disk diffusion was predictive of time killing curve results.  
The study has been presented in part at the Infectious Di-
seases Accademy (IDA), Riunioni delle Scuole di Specializ-
zazione in Malattie Infettive e Tropicali, Udine, 5-6 Luglio 
2007. 
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